{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Normal+Saline+%280.9%25+Sodium+Chloride%29+injection&page=15",
    "query": {
      "intervention": "0.9% Normal Saline (0.9% Sodium Chloride) injection",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 496,
    "total_pages": 50,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Normal+Saline+%280.9%25+Sodium+Chloride%29+injection&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Normal+Saline+%280.9%25+Sodium+Chloride%29+injection&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T13:06:32.800Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03027661",
      "title": "Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2017-08-01",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2018-11-15",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03027661"
    },
    {
      "nct_id": "NCT03399370",
      "title": "Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ASCVD",
        "Elevated Cholesterol"
      ],
      "interventions": [
        {
          "name": "Inclisiran Sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Medicines Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1561,
      "start_date": "2017-12-21",
      "completion_date": "2019-09-17",
      "has_results": true,
      "last_update_posted_date": "2020-10-05",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 145,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03399370"
    },
    {
      "nct_id": "NCT05560477",
      "title": "Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Meniscus Tear"
      ],
      "interventions": [
        {
          "name": "AM3101",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 74,
      "start_date": "2023-04-26",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05560477"
    },
    {
      "nct_id": "NCT03518125",
      "title": "BARDA Securing Anthrax Immunity For the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "BioThrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride injection USP, 0.9% (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2018-05-09",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 4,
      "location_summary": "Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03518125"
    },
    {
      "nct_id": "NCT05274568",
      "title": "Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease",
        "Multisystem Atrophy",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "[18F]UCB-2897",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Invicro",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2022-01-31",
      "completion_date": "2023-10-25",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05274568"
    },
    {
      "nct_id": "NCT07571889",
      "title": "Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain From onabotulinumtoxinA Injections"
      ],
      "interventions": [
        {
          "name": "onabotulinumtoxinA prophylaxis with Lidocaine",
          "type": "PROCEDURE"
        },
        {
          "name": "OnabotulinumtoxinA prophylaxis with Saline",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Association of Migraine Disorders",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-03-03",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 1,
      "location_summary": "East Providence, Rhode Island",
      "locations": [
        {
          "city": "East Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07571889"
    },
    {
      "nct_id": "NCT04764448",
      "title": "A Study of Belcesiran in Patients With AATLD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Belcesiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-02-12",
      "completion_date": "2024-05-29",
      "has_results": true,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Gainesville, Florida • Charleston, South Carolina",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04764448"
    },
    {
      "nct_id": "NCT04977479",
      "title": "The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Allergic Reaction"
      ],
      "interventions": [
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "16 Years to 69 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-08",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04977479"
    },
    {
      "nct_id": "NCT06695117",
      "title": "Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Immunization",
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "IIV-HD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% NaCl)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 980,
      "start_date": "2024-11-19",
      "completion_date": "2026-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06695117"
    },
    {
      "nct_id": "NCT02661490",
      "title": "Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Norovirus"
      ],
      "interventions": [
        {
          "name": "Norovirus GI.1/GII.4 Bivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% sodium chloride (saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2016-02-01",
      "completion_date": "2017-09-29",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-10-15T13:06:32.800Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661490"
    }
  ]
}